DOCSLIB.ORG

New Drugs 1998

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Drugs 1998 Tom Frank, Pharm.D., BCPS Discloses that he is on the speaker’s bureau of Pfizer, Novartis and Amgen 1 Dabigatran • Oral anticoagulant indicated to reduce the risk of stroke and systemic embolism • Non-valvular atrial fibrillation • Direct thrombin (factor IIa) inhibitor • Inhibition of thrombin decreases the conversion of fibrinogen to fibrin • Also inhibits free thrombin, fibrin bound thrombin and thrombin induced platelet aggregation 2 Dabigatran Pharmacokinetics • Hydrolyzed to active moiety • Metabolized to four glucuronides, all are active • Bioavailability 3-7% (do not crush or open capsule) • Peak concentration in one hour • Protein binding 35% • Eliminated primarily in urine • Half life 12-17 hours • Adjust dose for diminished renal function Dabigatran Pharmacokinetics • Drug interactions: • Rifampin (reduced dabigatran levels) • No changes other than Cmax or AUC seen when used with ketoconazole, verapamil, amiodarone, quinidine, clarithromycin • No changes in coagulation when given with given clopidogrel or enoxaparin • No change in dabigatran levels when given with digoxin, H2 blockers or PPI’s • Pharmacodynamics: median aPTT 2x control onset of therapeutic effect between 30 min and 2 hours 3 Dabigatran Clinical Trials • Dabigatran 110mg or 150mg twice daily compared to warfarin (INR 2-3) • Patients with atrial fibrillation and risk factors for stroke • Primary end point: rate of stroke or systemic embolism • Primary safety outcome: rate of major hemorrhage • Low dose aspirin or other anti-platelet allowed • Primary end point: dabigatran 110mg 1.53%/yr; 150mg 1.11%/yr and 1.69%/yr for warfarin • Primary safety end point: dabigatran 110mg 0.12%/yr, 150mg 0.10%/yr and 0.38%/yr for warfarin Dabigatran Adverse Effects • Dyspepsia • Intracranial hemorrhage • Life threatening bleed • Major bleeding • Major GI bleeding • Rates of MI from RE-LY: 0.82% for 110mg, 0.81% for 150mg and 0.64% for warfarin 4 Dabigatran Dosing • 150mg p.o. twice daily • 75mg p.o. twice daily if CrCl 15-30ml/min • If switching from warfarin, stop warfarin and start dabigatran when the INR < 2 • If switching from parenteral anticoagulant, start dabigatran less than 2 hours before next injection would have been given OR at the time IV heparin is discontinued • Discontinue 1-2 days prior to elective surgery; check ECT or aPTT if emergent surgery 5 Denosumab • Human monoclonal antibody indicated for the treatment of postmenopausal women with osteoporosis at a high risk for fracture • Denosumab binds to the RANK ligand and inhibits maturation of osteoclasts • Denosumab mimics the effects of osteoprotegerin 6 7 Denosumab Pharmacokinetics • Bioavailability 100% • Levels detectable within one hour • Half life 25 days • Metabolized by RES • Drug interactions: not studied Denosumab Clinical Trials • Placebo controlled trial evaluating denosumab 60mg SQ every 6 months • Female patients with low T-score at hip or spine • End point: new vertebral fracture at 36 months • Secondary end points: time to first non-vertebral fracture and time to hip fracture • End point reached in 7.2% on placebo and 2.3% on denosumab • Non-vertebral fractures: 8% vs 6.5%; hip fracture rate 1.2% vs 0.7% 8 Denosumab Clinical Trials • Randomized, double blind, placebo controlled trial evaluated denosumab 60mg every six months in men on androgen deprivation therapy for prostate cancer • End point: BMD change after 24 months • Denosumab group improved by 5.6%, placebo group decreased by 1% • New vertebral fractures: 1.5% vs 3.9% Denosumab Adverse Effects • Hypocalcemia • Non-fatal serious infections • New malignancies • Dermatologic reaction • Osteonecrosis of the jaw • Pancreatitis 9 Denosumab Dosing • 60mg subcutaneously every 6 months • Inject into upper arm, thigh or abdomen • Should be administered by healthcare professional • Patient should be taking calcium and vitamin D 10 Belimumab • Human monoclonal antibody indicated for patients with active SLE who are receiving standard therapy • B-lymphocyte stimulator (BLyS) protein inhibitor • Blocks binding of BLyS to receptors on B-cells • Inhibited B-cell survival and reduced differentiation of B-cells Belimumab Pharmacokinetics • Half life 19.4 days • No changes based on age, gender race or renal impairment • Drug interactions: steroids and ACEI produce increased clearance but no clinical impact; no impact with used with mycophenolate, azathioprine, methotrexate, antimalarials, NSAID’s, aspirin and HMGCoA reductase inhibitors 11 Belimumab Clinical Trials • Randomized double-blind, placebo-controlled trials in patients with active SLE disease (76 weeks and 52 weeks duration) • Stratified based on SELENA-SLEDAI score, proteinuria and race • >70% were on 2 or more SLE drugs • Patients with severe lupus nephritis or CNS lupus excluded • Assigned to 1mg/kg/day or 10mg/kg/day or placebo • Doses given on day 0, 14, 28 then every 28 days Belimumab Clinical Trials • SLE Responder Index end point reached in 41%, 43% and 43% respectively in 76 week trial • End point reached in 51%, 58% and 44% respectively in 52 week trial • Subgroup analysis: response rate in black/African American patients less than placebo in one study and similar response to other patients in second study 12 Belimumab Adverse Effects • Nausea • Diarrhea • Pyrexia • Death • Serious infections • Malignancy • Hypersensitivity reactions • Infusion reactions • Depression Belimumab Dosing • 10mg/kg at two weeks intervals for first three doses and four week intervals after that • IV infusion given over one hour • Can pre-medicate for infusion reactions 13 Ulipristal • Progesterone agonist/antagonist indicated for emergency contraception • Selective progesterone receptor modulator • Binds to progesterone, glucocorticoid and androgen receptors • Primary mechanism of action is inhibition or delay of ovulation 14 Ulipristal Pharmacokinetics • Highly protein bound • Peak concentration in one hour • Presence of food does not require dose adjustment • Metabolized by CYP 3A4 • Half life 32 hours • Drug interactions: CYP 3A4 inducers (barbiturates, carbamazepine, felbamate, rifampin, St. John’s wort, topiramate) Ulipristal Clinical Trials • Open-label trial; ulipristal 30mg in women who presented for emergency contraception within 48-120 hours after unprotected intercourse; 27 pregnancies (observed rate 2.2%, expected rate 5.5%) • Ulipristal 30mg compared to levonorgestrel 1.5mg in single blind trial • Stratified according to time since unprotected intercourse • Taken with 72 hours: pregnancy rates were ulipristal 1.8% and levonorgestrel 2.6% • Between 72-120 hours: ulipristal no pregnancies, levonorgestrel 3% pregnancy rate 15 Ulipristal Adverse Effects • Headache • Abdominal pain • Nausea • Dysmenorrhea • Fatigue • Dizziness • Rapid return of fertility likely • Cycle length increased by mean of 2.5 days Ulipristal Dosing • Take one tablet orally as soon as possible within 120 hours after unprotected intercourse or a known or suspected contraceptive failure 16 Dienogest/estradiol valerate • Indicated for preventing pregnancy in women with BMI < 30kg/m2 • Estradiol inhibits ovulation • Dienogest potent progestin with anti- androgenic activity- thicken cervical mucus and changes in endometrium • Packaged in four-phase dose configuration 17 Dienogest/ethinyl estradiol Pharmacokinetics • Peak estrogen level in 3 hours, peak progestin levels in 1.5 hours • Estradiol 2-3% circulates free, dienogest 10% circulates free • Metabolism by CYP 3A4 • Half life: estradiol 14 hours, dienogest 11 hours • Drug interactions: drugs that induce CYP 3A4 (decrease efficacy/BTB); do not use with strong CYP 3A4 inducers; strong CYP 3A4 inhibitors increase hormone concentrations; protease inhibitors Dienogest/estradiol valerate Clinical Trials • Open-label, single-arm study • Treated for up to 28 cycles • 3,969 exposure cycles • 5 pregnancies identified in 13 cycle window • Pearl Index of 1.64 • Contraceptive failure rate after a year of 0.016 on Kaplan Meier curve 18 Dienogest/estradiol valerate Clinical Trials • Dienogest/estradiol compared to levonorgestrel/EE over seven cycles to compare withdrawal bleeding patterns • Withdrawal bleeding on schedule: dienogest/estradiol- 77-83% compared to levonorgestrel/EE 89-93% of the time • Duration of withdrawal bleeding: dienogest/estradiol- 4.1-4.7 days; levonorgestrel/EE- 5.0-5.2 days • Breakthrough bleeding rates 14% vs 12% Dienogest/estradiol valerate Adverse Effects • Headache • Metrorrhagia and irregular menstruation • Breast pain • Nausea or vomiting • Acne • Increased weight 19 3.5 3 2.5 2 yellow = 1.5 Estradiol green= 1 Dienogest 0.5 0 Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day 1 3 5 7 9 11 13 15 17 19 21 23 25 27 28 Dienogest/estradiol valerate Dosing • One tablet once a day (note different tablet colors associated with varying content) • Response to missed pills depends on which pill was missed • Start on first day of menses 20 The time to onset of therapeutic effect (aPTT > 2x control) for dabigatran is 1 hour 6 hours 2-3 days One week 21 Ceftaroline • “Next generation” cephalosporin indicated for treatment of acute bacterial skin and skin structure infections and community acquired pneumonia • Unique binding properties among cephalosporins for PBP2a • Good activity for MRSA and streptococci including multi-drug resistant Streptococcus pneumoniae • Lacks enterococcus coverage, limited gram negative spectrum Ceftaroline Pharmacokinetics • Low protein binding • Converted to active form by phosphatase enzyme • Half life 2.6 hours
Load more

Recommended publications
  • STIM1 Controls Calcineurin/Akt/Mtor/NFATC2‑Mediated Osteoclastogenesis Induced by RANKL/M‑CSF
    736 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20: 736-747, 2020 STIM1 controls calcineurin/Akt/mTOR/NFATC2‑mediated osteoclastogenesis induced by RANKL/M‑CSF YANJIAO HUANG1, QIANG LI2, ZUNYONG FENG3 and LANRONG ZHENG1 Departments of 1Pathological Anatomy, 2Anatomy and 3Forensic Medicine, Wannan Medical College, Wuhu, Anhui 241002, P.R. China Received October 15, 2018; Accepted June 20, 2019 DOI: 10.3892/etm.2020.8774 Abstract. Store-operated Ca2+ entry (SOCE) is the stable (p.E136X, p.R429C) or constitutively activated (p.R304W) calcium channel influx in most cells. It consists of the SOCE, failed to respond to RANKL/M-CSF-mediated induc- cytoplasmic ion channel ORAI and endoplasmic reticulum tion of normal osteoclastogenesis. In addition, activation of the receptor stromal interaction molecule 1 (STIM1). Abolition calcineurin/Akt/mTOR/NFATC2 signalling cascade induced of SOCE function due to ORAI1 and STIM1 gene defects by RANKL/M-CSF was abnormal in the BMDMs with may cause non-perspiration, ectoderm dysplasia and STIM1 mutants compared with that in BMDMs from healthy skeletal malformations with severe combined immunodefi- subjects. In addition, overexpression of wild-type STIM1 ciency (CID). Calcineurin/mammalian target of rapamycin restored SOCE in p.R429C- and p.E136X-mutant BMDMs, but (mTOR)/nuclear factor of activated T cells 2 (NFATC2) is not in p.R304W-mutant BMDMs. Of note, calcineurin, cyclo- an important signalling cascade for osteoclast development. sporin A, mTOR inhibitor rapamycin and NFATC2‑specific Calcineurin is activated by Ca2+ via SOCE during osteoclas- small interfering RNA restored the function of SOCE in togenesis, which is induced by receptor activator of NF-κB p.R304W-mutant BMDMs.
    [Show full text]
  • Denosumab and Anti-Angiogenetic Drug-Related Osteonecrosis of the Jaw: an Uncommon but Potentially Severe Disease
    ANTICANCER RESEARCH 33: 1793-1798 (2013) Denosumab and Anti-angiogenetic Drug-related Osteonecrosis of the Jaw: An Uncommon but Potentially Severe Disease STEFANO SIVOLELLA1, FRANCO LUMACHI2, EDOARDO STELLINI1 and LORENZO FAVERO1 Departments of 1Neurosciences, Section of Dentistry and 2Surgery, Oncology and Gastroenterology, University of Padua, School of Medicine, Padova, Italy Abstract. Osteonecrosis of the jaw (ONJ) is a rare but bone exposure in the oral cavity (1). Experimental radio-ONJ serious lesion of the jaw characterized by exposed necrotic was first reported in the 1960s and better-described by Zach bone and is related to several drugs usually used for treating et al. (2, 3). Currently, ONJ may represent a serious problem patients with advanced malignancies. Common therapies in patients irradiated for head and neck carcinomas, but may inducing ONJ are nitrogen-containing bisphosphonates (BPs), also be an uncommon complication of cancer chemotherapy the human monoclonal antibody to the receptor activator of (4, 5). Other causes of ONJ are local malignancy, periodontal nuclear factor-kappa B ligand denosumab and some anti- disease, trauma, and long-term glucocorticoid or angiogenic drugs, alone or in combination with BPs. The real bisphosphonate (BP) therapy (6). ONJ is a potentially incidence of ONJ is unknown. Several cases of ONJ in patients debilitating disease, which occurs in approximately 5% of with cancer who underwent denosumab therapy have been patients with myeloma or bone metastases from breast cancer reported and it seems that the overall incidence of denosumab- (BC) or prostate cancer receiving high-dose intravenous BPs related ONJ is similar to that for BP-related in this (7).
    [Show full text]
  • Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: an Overview
    Journal of Clinical Medicine Review Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview Yoshiya Tanaka The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Kitakyushu 807-8555, Japan; [email protected]; Tel.: +81-93-603-1611; Fax: +81-93-691-7580 Abstract: In rheumatoid arthritis, a representative systemic autoimmune disease, immune abnor- mality and accompanying persistent synovitis cause bone and cartilage destruction and systemic osteoporosis. Biologics targeting tumor necrosis factor, which plays a central role in the inflammatory process, and Janus kinase inhibitors have been introduced in the treatment of rheumatoid arthritis, making clinical remission a realistic treatment goal. These drugs can prevent structural damage to bone and cartilage. In addition, osteoporosis, caused by factors such as menopause, aging, immobility, and glucocorticoid use, can be treated with bisphosphonates and the anti-receptor activator of the nuclear factor-κB ligand antibody. An imbalance in the immune system in rheumatoid arthritis induces an imbalance in bone metabolism. However, osteoporosis and bone and cartilage destruction occur through totally different mechanisms. Understanding the mechanisms underlying osteo- porosis and joint destruction in rheumatoid arthritis leads to improved care and the development of new treatments. Keywords: rheumatoid arthritis; osteoporosis; joint destruction; DMARD; biologics Citation: Tanaka, Y. Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J. Clin. Med. 2021, 10, 1. Introduction 1241. https://doi.org/10.3390/ Rheumatoid arthritis is a systemic autoimmune disease characterized by inflammatory jcm10061241 polyarthritis. It occurs commonly in women in their 30s to 60s, and often causes organ disorders.
    [Show full text]
  • Paracrine and Endocrine Actions of Bone—The Functions of Secretory
    Bone Research www.nature.com/boneres REVIEW ARTICLE OPEN Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts Yujiao Han1, Xiuling You1, Wenhui Xing1, Zhong Zhang1 and Weiguo Zou 1 The skeleton is a dynamic organ that is constantly remodeled. Proteins secreted from bone cells, namely osteoblasts, osteocytes, and osteoclasts exert regulation on osteoblastogenesis, osteclastogenesis, and angiogenesis in a paracrine manner. Osteoblasts secrete a range of different molecules including RANKL/OPG, M-CSF, SEMA3A, WNT5A, and WNT16 that regulate osteoclastogenesis. Osteoblasts also produce VEGFA that stimulates osteoblastogenesis and angiogenesis. Osteocytes produce sclerostin (SOST) that inhibits osteoblast differentiation and promotes osteoclast differentiation. Osteoclasts secrete factors including BMP6, CTHRC1, EFNB2, S1P, WNT10B, SEMA4D, and CT-1 that act on osteoblasts and osteocytes, and thereby influenceaA osteogenesis. Osteoclast precursors produce the angiogenic factor PDGF-BB to promote the formation of Type H vessels, which then stimulate osteoblastogenesis. Besides, the evidences over the past decades show that at least three hormones or “osteokines” from bone cells have endocrine functions. FGF23 is produced by osteoblasts and osteocytes and can regulate phosphate metabolism. Osteocalcin (OCN) secreted by osteoblasts regulates systemic glucose and energy metabolism, reproduction, and cognition. Lipocalin-2 (LCN2) is secreted by osteoblasts and can influence energy metabolism by suppressing appetite in the brain. We review the recent progresses in the paracrine and endocrine functions of the secretory proteins of osteoblasts, osteocytes, and osteoclasts, revealing connections of the skeleton with other tissues and providing added insights into the pathogenesis of degenerative diseases affecting multiple organs and the drug discovery process.
    [Show full text]
  • Denosumab, Cortical Bone and Bone Erosions in Rheumatoid Arthritis
    ARD Online First, published on June 23, 2016 as 10.1136/annrheumdis-2016-210022 Correspondence Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-210022 on 23 June 2016. Downloaded from Denosumab, cortical bone and bone erosions University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, Verona 37134, in rheumatoid arthritis Italy; [email protected] Competing interests None declared. Ta ke u c h i et al1 demonstrate an additional inhibitory effect on the Provenance and peer review Not commissioned; internally peer reviewed. progression of bone erosions in rheumatoid arthritis (RA) with the To cite Rossini M, Adami G, Viapiana O, et al. Ann Rheum Dis Published Online addition to methotrexate of an anti-receptor activator of nuclear First: [please include Day Month Year] doi:10.1136/annrheumdis-2016-210022 factor kappa-B ligand (RANKL) antibody, denosumab, confirming Accepted 6 June 2016 2 results already reported 8 years ago by Cohen and colleagues. Ann Rheum Dis 2016;0:1. doi:10.1136/annrheumdis-2016-210022 Insufficient inhibition of structural joint damage by disease- modifying antirheumatic drugs (DMARDs) was reported despite – clinical improvement,3 5 and recently two meta-analysis67showed REFERENCES 1 Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients that methotrexate combined with biologics is statistically superior with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in to methotrexate in inhibiting radiographic progression, but the patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on estimated mean change with all treatments was less than the bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, minimal clinically important difference.
    [Show full text]
  • Osteonecrosis of the Jaws Produced by Sunitinib
    Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e326-38. Osteonecrosis of the jaws produced by sunitinib Journal section: Oral Medicine and Pathology doi:10.4317/medoral.22858 Publication Types: Review http://dx.doi.org/doi:10.4317/medoral.22858 Osteonecrosis of the jaws produced by sunitinib: a systematic review Carmen Vallina 1, Lucía Ramírez 2, Jesús Torres 3, Elisabeth Casañas 4, Gonzalo Hernández 5, Rosa-María López-Pintor 6 1 DDS, Oral Medicine Postgraduate. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain 2 DDS, PhD Student, Oral Medicine Postgraduate. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain 3 DDS, PhD, Professor. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain 4 DDS, PhD, Researcher, Oral Medicine Postgraduate. Department of Dental Clinical Specialties. School of Dentistry. Com- plutense University, Madrid, Spain 5 MD, DDS, PhD, Professor, Director Specialty in Oral Medicine. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain 6 DDS, PhD, Associate Professor, Co-director Speciality in Oral Medicine. Department of Dental Clinical Specialties. School of Dentistry. Complutense University, Madrid, Spain Correspondence: Departamento de Especialidades Clínicas Odontológicas Facultad de Odontología Universidad Complutense de Madrid Plaza Ramón y Cajal S/N 28040-Madrid Spain Vallina C, Ramírez L, Torres J, Casañas E, Hernández G, López-Pintor [email protected] RM. Osteonecrosis of the jaws produced by sunitinib: a systematic re- view. Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e326-38. http://www.medicinaoral.com/medoralfree01/v24i3/medoralv24i3p326.pdf Received: 22/08/2018 Article Number: 22858 http://www.medicinaoral.com/ Accepted: 10/12/2018 © Medicina Oral S.
    [Show full text]
  • Denosumab (Prolia™, XGEVA™)
    Corporate Medical Policy Denosumab (Prolia™, XGEVA™) File Name: denosumab_prolia_xgeva Origination: 3/2011 Last CAP Review: 9/2018 Next CAP Review: 9/2019 Last Review: 5/2019 Description of Procedure or Service Receptor activator of nuclear factor-κB ligand (RANKL), a protein expressed by osteoblastic stromal cells, binds to receptor activator of nuclear factor-κB (RANK) and is the primary mediator of osteoclast differentiation, activation, and survival. RANKL is responsible for osteoclast-mediated bone resorption in a broad range of conditions. Osteoprotegerin, a soluble RANKL decoy receptor that binds RANKL, is the key endogenous regulator of the RANKL– RANK pathway. Denosumab (formerly known as AMG 162, Amgen) is a fully human monoclonal antibody (IgG2) that binds to RANKL with high affinity and specificity and blocks the interaction of RANKL with RANK, mimicking the endogenous effects of osteoprotegerin. In a phase 1 dose-escalation study, a single subcutaneous injection of denosumab resulted in a dose-dependent decrease in bone resorption, as measured by changes in serum and urinary N-telopeptide, markers of osteoclastic bone resorption. Denosumab is marketed under the trade name XGEVA™ for the prevention of skeletal-related events in cancer patients with multiple myeloma or with bone metastases from solid tumors and for treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. XGEVA™ is also indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. XGEVA™ is supplied as an injection of 120 mg denosumab/1.7 mL (70 mg/mL) solution in a single-use vial for subcutaneous injection.
    [Show full text]
  • Denosumab (Prolia) Is a Biologic Medication Used to Which Normally Causes Bone Turnover
    Denosumab PATIENT FACT SHEET (Prolia) Denosumab (Prolia) is a biologic medication used to which normally causes bone turnover. By blocking prevent fragile bones, also known as osteoporosis, RANKL, it helps to strengthen bones. Denosumab is and bone fractures. As a biologic drug, it is synthetic generally not viewed as the first treatment given in and closely resembles naturally-occurring antibodies in osteoporosis but rather when they are unable to take WHAT IS IT? the body. In this case, it stops a molecule, called RANKL, bisphosphonates or have unsuccessful results. Denosumab is given as an injection just under the works quickly—within three days of an injection, the skin. It is given by your doctor or nurse. The usual effects on reducing bone turnover can be detected in dose is 60 mg every six months, and it should be the blood; the drug also stays in the blood for several taken with calcium (1000-1200 mg daily) and vitamin months after stopping the medicine. D (at least 400 IU) supplementation. Denosumab HOW TO TAKE IT The most common side effects that patients experience infections (especially if you’re already taking medications are back pain, pain in the hands and feet, and increased that lower your immune system), low calcium levels (called cholesterol. The pain from denosumab can last a few hypocalcemia), loss of blood supply to the jawbone (called days up to a few months after administration. The rarer, osteonecrosis of the jaw), atypical fracture of the leg, and but worrisome side effects include an increased risk for severe allergic reactions.
    [Show full text]
  • White Spot Lesions After Orthodontic Treatment Assessed by Clinical
    ABSTRACTS OTHER JOURNALS IN BRIEF A selection of abstracts of clinically relevant papers from other journals. The abstracts on this page have been chosen and edited by John R. Radford. DENOSUMAB – DENTAL HEALTH REPAIRING FRACTURED CERAMIC Denosumab, an alternative to bisphosphonates but also Surface treatments for repair of feldspathic, leucite- associated with osteonecrosis of the jaw − what is the risk? and lithium disilicate-reinforced glass ceramics using Sidhu HK. Dent Update 2015; 42: 436–440 composite resin Dental health to be secured before and during denosumab therapy. Neis CA, Albuquerque NL et al. Braz Dent J 2015; 26: 152–155 No single method for treating the surface of fractured different types of Correspondence in the Letters section of this Journal (eg Br Dent J ceramic before placement of resin composite. 2014; 217: 258–259) have reported that new drugs, such as deno- sumab (Prolia®, XGEVA®), and the antiangiogenic agents bevaci- The investigators found that 1) hydrofluoric acid (10%) should be zumab (Avastin®) and sunitinib (Sutent®), of course in addition to used to surface condition damaged lithium disilicate ceramic (IPS bisphosphonates, are associated with osteonecrosis of the jaw (ONJ). e.max Press, Ivoclar Vivadent), whereas 2) use of a diamond bur This review describes the mechanisms of action and therapeutics (30 µm grit) is sufficient for leucite-reinforced glass ceramic (IPS of denosumab and bisphosphonates. Denosumab is a monoclonal Empress, Ivoclar Vivadent). An alternative method for treating leu- human antibody that has bone antiresorptive properties. It is used cite-reinforced ceramic would be the use of tribochemical process. to prevent osteoporotic fractures in postmenopausal women who The use of hydrofluoric acid lowered the bond strength between cannot take bisphosphonates, and prevention of skeletal-related resin composite and leucite-reinforced glass ceramic.
    [Show full text]
  • The Differential Effects of Two Critical Osteoclastogenesis Stimulating Factors on Bone Biomechanics Yuyu Yuan Clemson University, [email protected]
    Clemson University TigerPrints All Dissertations Dissertations 5-2007 The Differential Effects of Two Critical Osteoclastogenesis Stimulating Factors on Bone Biomechanics Yuyu Yuan Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Biomedical Engineering and Bioengineering Commons Recommended Citation Yuan, Yuyu, "The Differential Effects of Two Critical Osteoclastogenesis Stimulating Factors on Bone Biomechanics" (2007). All Dissertations. 416. https://tigerprints.clemson.edu/all_dissertations/416 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. THE DIFFERENTIAL EFFECTS OF TWO CRITICAL OSTEOCLASTOGENESIS STIMULATING FACTORS ON BONE BIOMECHANICS ________________________ A Dissertation Presented to the Graduate School of Clemson University ________________________ In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Bioengineering ________________________ by Yuyu Yuan May 2007 ________________________ Accepted by: Dr. Ted Bateman, Committee Chair Dr. Karen Burg Dr. Sarah Harcum Dr. Dan Simionescu Dr. Naren Vyavahare ABSTRACT Many skeletal diseases, such as osteoporosis and malignant bone metastases, are generally osteolytic and associated with increased bone resorption and decreased bone strength. Within a complex cytokine
    [Show full text]
  • Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
    viruses Review Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak Zheng Yao Low 1 , Isra Ahmad Farouk 1 and Sunil Kumar Lal 1,2,* 1 School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia; [email protected] (Z.Y.L.); [email protected] (I.A.F.) 2 Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia * Correspondence: [email protected] Received: 3 July 2020; Accepted: 21 August 2020; Published: 22 September 2020 Abstract: Traditionally, drug discovery utilises a de novo design approach, which requires high cost and many years of drug development before it reaches the market. Novel drug development does not always account for orphan diseases, which have low demand and hence low-profit margins for drug developers. Recently, drug repositioning has gained recognition as an alternative approach that explores new avenues for pre-existing commercially approved or rejected drugs to treat diseases aside from the intended ones. Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well accessed and approved by regulatory authorities. The greatest advantage of drug repositioning is that it breathes new life into the novel, rare, orphan, and resistant diseases, such as Cushing’s syndrome, HIV infection, and pandemic outbreaks such as COVID-19. Repositioning existing drugs such as Hydroxychloroquine, Remdesivir, Ivermectin and Baricitinib shows good potential for COVID-19 treatment. This can crucially aid in resolving outbreaks in urgent times of need.
    [Show full text]
  • Denosumab – Osteoporosis Medical Drug Program Summary
    Denosumab – Osteoporosis Medical Drug Program Summary FDA APPROVED INDICATIONS AND DOSAGE1 Agent(s) Indication(s) Dosage Prolia® • Treatment of The recommended dose is 60 (denosumab) postmenopausal women with mg via subcutaneous osteoporosis at high risk for injection once every 6 Subcutaneous injection fracture, defined as a history months. Denosumab should of osteoporotic fracture, or be administered by a multiple risk factors for healthcare professional. All fracture; or patients who patients should receive have failed or are intolerant calcium 1000 mg daily and at to other available least 400 IU of vitamin D osteoporosis therapy. daily. • Treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. • Treatment of glucocorticoid- induced osteoporosis in men and women at high risk for fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. • Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. • Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. KS_PS_MDC_Denosumab_Osteoporosis_ProgSum_AR0920_r0621 Page 1 of 9 © Copyright Prime Therapeutics
    [Show full text]